


**AMENDMENTS TO THE CLAIMS:**

Without prejudice or disclaimer, this listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) A compound represented by the general formula (I):



wherein R<sup>1</sup> is a hydrogen atom, halogen atom, C1-C6 alkyl, or C1-C12 alkyloxy;

R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or two substituent(s) selected from substituent group A, C2-C15 alkenyl optionally substituted with one or two substituent(s) selected from substituent group A, C2-C15 alkynyl optionally substituted with one or two substituent(s) selected from substituent group A, C3-C8 cycloalkyl, C1-C15 alkyloxy optionally substituted with one or two substituent(s) selected from substituent group A, or phenyl optionally substituted with one or two substituent(s) selected from substituent group A;

R<sup>5</sup> is a hydrogen atom, a halogen atom, C1-C3 alkyl, or C1-C3 alkyloxy;

R<sup>6</sup> is a hydrogen atom, a halogen atom, or C1-C3 alkyl;

R<sup>7</sup> is a halogen atom or C1-C3 alkyl;

R<sup>8</sup> is a halogen atom, C1-C3 alkyl, or C1-C3 alkyloxy;

R<sup>9</sup> is a hydrogen atom or C1-C6 alkyl; or

R<sup>1</sup> and R<sup>5</sup> are taken together with the adjacent carbon atoms may form a 5 to 8 membered ring which may contain a heteroatom and /or an unsaturated bond, wherein the ring may be substituted with one or two C1-C8 alkyl;

provided that when R<sup>2</sup> and R<sup>3</sup> are a chlorine atom, R<sup>6</sup> is not a hydrogen atom;

substituent group A consists of halogen atom, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, phenyl, naphthyl, pyridyl, oxolanyl, cyano, C1-C12 alkyloxy, C2-C12 alkenyloxy, C2-C12 alkynyloxy, C3-C8 cycloalkyl-C1-C8 alkyloxy, phenyl-C1-C8 alkyloxy, naphthyl-C1-C8 alkyloxy, C1-C8 alkyloxy-C1-C8 alkyloxy, (C1-C8 alkyloxy - C1-C8 alkyloxy)C1-C8 alkyloxy, di(C1-C8 alkyloxy)C1-C8 alkyloxy, oxolanyl-C1-C8 alkyloxy, haloC1-C8 alkyloxy, C3-C8 cycloalkyloxy, amino optionally substituted with C1-C8 alkyl, C1-C8 alkylthio, and C1-C8 alkylthio-C1-C8 alkyloxy; a pharmaceutically acceptable salt, or solvate thereof.

2. (Original) A compound of claim 1, wherein both of R<sup>6</sup> and R<sup>7</sup> are fluorine atom or chlorine atom, a pharmaceutically acceptable salt, or solvate thereof.

3. (Original) A compound of claim 1, wherein R<sup>5</sup> is a hydrogen atom or C1-C3 alkyloxy, a pharmaceutically acceptable salt, or solvate thereof.


4. (Original) A compound of claim 1, wherein R<sup>8</sup> is methyl or methyloxy, a pharmaceutically acceptable salt, or solvate thereof.

5. (Original) A compound of any one of claims 1 to 4, wherein R<sup>2</sup> is C1-C15 alkyl optionally substituted with one or two substituent(s) selected from substituent group A, C2-C15 alkynyl optionally substituted with one or two substituent(s) selected from substituent group A, or C1-C15 alkyloxy optionally substituted with one or two

substituent(s) selected from substituent group A, a pharmaceutically acceptable salt, or solvate thereof.

6. (Original) A compound of any one of claims 1 to 4, wherein  $R^2$  is C1-C12 alkyl optionally substituted with one or two C1-C8 alkyloxy, and both of  $R^3$  and  $R^4$  are a hydrogen atom, a pharmaceutically acceptable salt, or solvate thereof.

7. (Currently Amended) A compound represented by the general formula (II):



wherein  $R^A$  is a hydrogen atom, C1-C12 alkyloxy, C1-C8 alkyloxy-C1-C8 alkyloxy or (C1-C8 alkyloxy-C1-C8 alkyloxy)C1-C8 alkyloxy;

$R^B$  is C1-C14 alkyl optionally substituted with one or two substituent(s) selected from substituent group B, C2-C14 alkynyl optionally substituted with one or two substituent(s) selected from substituent group B, C3-C8 cycloalkyl, C1-C14 alkyloxy optionally substituted with one or two substituent(s) selected from substituent group B, phenyl, or naphthyl;

$R^C$  is a hydrogen atom, halogen atom, C1-C6 alkyl, or C1-C12 alkyloxy;

$R^D$  is a hydrogen atom, halogen atom, C1-C3 alkyl, or C1-C3 alkyloxy;

$R^6$  and  $R^7$  are each independently halogen atom or C1-C3 alkyl;

$R^8$  is halogen atom, C1-C3 alkyl, or C1-C3 alkyloxy;

substituent group B consists of halogen atom, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, phenyl, naphthyl, pyridyl, oxolanyl, cyano, C1-C8 alkyloxy, C2-C8

alkenyloxy, C2-C8 alkynyloxy, C3-C8 cycloalkyl-C1-C8 alkyloxy, phenyl-C1-C8 alkyloxy, naphthyl-C1-C8 alkyloxy, C1-C8 alkyloxy-C1-C8 alkyloxy, (C1-C8 alkyloxy-C1-C8 alkyloxy)C1-C8 alkyloxy, di(C1-C8 alkyloxy)C1-C8 alkyloxy, oxolanyl-C1-C8 alkyloxy, haloC1-C8 alkyloxy, C3-C8 cycloalkyloxy, amino optionally substituted with C1-C8 alkyl, C1-C8 alkylthio, and C1-C8 alkylthio-C1-C8 alkyloxy;  
a pharmaceutically acceptable salt, or solvate thereof.

8. (Original) A compound of claim 7, wherein both of  $R^6$  and  $R^7$  are fluorine atom or chlorine atom, a pharmaceutically acceptable salt, or solvate thereof.

9. (Original) A compound of claim 7, wherein  $R^8$  is methyl or methyloxy, a pharmaceutically acceptable salt, or solvate thereof.


10. (Original) A compound of claim 7, wherein  $R^C$  is fluorine atom or C1-C3 alkyloxy, a pharmaceutically acceptable salt, or solvate thereof.

11. (Original) A compound of any one of claims 7 to 10, wherein  $R^A$  is C1-C8 alkyloxy;  $R^B$  is C1-C11 alkyl optionally substituted with one or two substituent(s) selected from substituent group B, or C2-C11 alkynyl optionally substituted with one or two substituent(s) selected from substituent group B, a pharmaceutically acceptable salt, or solvate thereof.

12. (Original) A compound of claim 7, wherein  $R^C$  is fluorine atom or C1-C3 alkyloxy,  $R^D$  is a hydrogen atom or C1-C3 alkyloxy, both of  $R^6$  and  $R^7$  are fluorine atom or chlorine atom,  $R^8$  is methyl or methyloxy,  $R^A$  is C1-C3 alkyloxy,  $R^B$  is C8-C12 alkyl optionally substituted with one or two substituent(s) selected from substituent group B, a pharmaceutically acceptable salt, or solvate thereof.

13 - 18: Cancelled.

19. (Original) A compound represented by the general formula (II-A):



wherein R<sup>C</sup> is a hydrogen atom, a halogen atom, C1-C6 alkyl, or C1-C12 alkyloxy;

R<sup>D</sup> is a hydrogen atom, a halogen atom, C1-C3 alkyl, or C1-C3 alkyloxy;

R<sup>F</sup> is C1-C14 alkyl optionally substituted with one or two substituent(s) selected from substituent group D, C2-C14 alkenyl optionally substituted with one or two substituent(s) selected from substituent group D, C2-C14 alkynyl optionally substituted with one or two substituent(s) selected from substituent group D, C1-C14 alkyloxy optionally substituted with one or two substituent(s) selected from substituent group C, C3-C8 cycloalkyl, or phenyl optionally substituted with one or two substituent(s) selected from substituent group D;

R<sup>6</sup> and R<sup>7</sup> are each independently halogen atom or C1-C3 alkyl;

R<sup>8</sup> is halogen atom, C1-C3 alkyl, or C1-C3 alkyloxy;

substituent group D consists of halogen atom, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, phenyl, naphthyl, pyridyl, oxolanyl, cyano, C1-C8 alkyloxy, C2-C8 alkenyloxy, C2-C8 alkynyloxy, C3-C8 cycloalkyl-C1-C8 alkyloxy, phenyl-C1-C8 alkyloxy, naphthyl-C1-C8 alkyloxy, C1-C8 alkyloxy-C1-C8 alkyloxy, (C1-C8 alkyloxy-C1-C8 alkyloxy)C1-C8 alkyloxy, di(C1-C8 alkyloxy)C1-C8 alkyloxy, oxolanyl-C1-C8 alkyloxy, haloC1-C8 alkyloxy, C3-C8 cycloalkyloxy, amino optionally substituted with C1-C8 alkyl, C1-C8 alkylthio, and C1-C8 alkylthio-C1-C8 alkyloxy;

a pharmaceutically acceptable salt, or solvate thereof.

20. (Original) A compound of claim 19, wherein both of R<sup>6</sup> and R<sup>7</sup> are fluorine atom or chlorine atom, a pharmaceutically acceptable salt, or solvate thereof.

21. (Original) A compound of claim 19, wherein R<sup>8</sup> is methyl or methyloxy, a pharmaceutically acceptable salt, or solvate thereof.

22. (Original) A compound of claim 19, wherein R<sup>C</sup> is fluorine atom or C1-C3 alkyloxy, a pharmaceutically acceptable salt, or solvate thereof.

23. (Previously Presented) A compound of any one of claims 19 to 22, wherein R<sup>F</sup> is C1-C14 alkyl optionally substituted with one or two substituent(s) selected from substituent group D, C2-C14 alkynyl optionally substituted with one or two substituent(s) selected from substituent group D, or C1-C14 alkyloxy optionally substituted with one or two substituent(s) selected from substituent group D, a pharmaceutically acceptable salt, or solvate thereof.

24. (Currently Amended) A pharmaceutical composition containing a compound as an active ingredient, a pharmaceutically acceptable salt, or solvate thereof of any one of claims 1 to 4, 7 to 10, or 19 to 2223.

25. (Currently Amended) A pharmaceutical composition containing a compound as an active ingredient, a pharmaceutically acceptable salt, or solvate thereof of any one of claims 1 to 4, 7 to 10, or 19 to 2223, ~~which is~~ in an amount effective for exhibiting thrombopoietin receptor agonism.

26. (Currently Amended) A pharmaceutical composition ~~platelet production modifier which contains a compound~~ containing a compound as an active ingredient, a

pharmaceutically acceptable salt, or solvate thereof of any one of claims 1 to 4, 7 to 10,  
or 19 to 22~~23~~ in an amount effective for modifying platelet production.

27. Cancelled.

28. (Currently Amended) A method for ~~modifying a platelet production-~~  
treating or preventing hemopathy of in a mammal, including a human, in need thereof,  
~~which comprises~~ comprising  
~~- administration administering~~ to said mammal ~~of a compound,~~ a pharmaceutically  
acceptable salt, or solvate thereof of any one of claims 1 to 4, 7 to 10, or 19 to 22 ~~23~~ in  
~~a pharmaceutically~~ an amount effective amount for modifying platelet production.